Earnings results for Xenetic Biosciences (NASDAQ:XBIO)
Xenetic Biosciences, Inc. is estimated to report earnings on 05/13/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.13. The reported EPS for the same quarter last year was $-0.19.
Xenetic Biosciences last issued its earnings results on March 15th, 2021. The reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.04. Xenetic Biosciences has generated $0.00 earnings per share over the last year. Xenetic Biosciences has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, May 13th, 2021 based off prior year’s report dates.
Analyst Opinion on Xenetic Biosciences (NASDAQ:XBIO)
2 Wall Street analysts have issued ratings and price targets for Xenetic Biosciences in the last 12 months. Their average twelve-month price target is $3.75, predicting that the stock has a possible upside of 109.50%. The high price target for XBIO is $5.00 and the low price target for XBIO is $2.50. There are currently 2 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Xenetic Biosciences has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $3.75, Xenetic Biosciences has a forecasted upside of 109.5% from its current price of $1.79. Xenetic Biosciences has received no research coverage in the past 90 days.
Dividend Strength: Xenetic Biosciences (NASDAQ:XBIO)
Xenetic Biosciences does not currently pay a dividend. Xenetic Biosciences does not have a long track record of dividend growth.
Insiders buying/selling: Xenetic Biosciences (NASDAQ:XBIO)
In the past three months, Xenetic Biosciences insiders have not sold or bought any company stock. Only 6.20% of the stock of Xenetic Biosciences is held by insiders. Only 3.19% of the stock of Xenetic Biosciences is held by institutions.
Earnings and Valuation of Xenetic Biosciences (NASDAQ:XBIO
Earnings for Xenetic Biosciences are expected to grow in the coming year, from ($0.74) to ($0.30) per share. Xenetic Biosciences has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.
More latest stories: here